New hope for tough cancers: pfizer tests experimental drug

NCT ID NCT07519655

First seen Apr 15, 2026 · Last updated May 04, 2026 · Updated 2 times

Summary

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung cancer, esophageal cancer, or melanoma that has spread or can't be removed. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants receive the drug in cycles and are closely monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Oncologico Dr. Isaac Gonzalez-Martinez

    RECRUITING

    Rio Piedras, 00935, Puerto Rico

  • Pan American Center for Oncology Trials, LLC

    RECRUITING

    Rio Piedras, 00935, Puerto Rico

  • Presbyterian/St Lukes Medical Center

    RECRUITING

    Denver, Colorado, 80218, United States

  • SCRI Oncology Partners

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute at HealthONE

    RECRUITING

    Denver, Colorado, 80218, United States

  • Sarah Cannon Research Institute- Pharmacy

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.